ST14抗體 targets the protein encoded by the ST14 gene, also known as matriptase, a transmembrane serine protease. First identified in the early 1990s, matriptase plays critical roles in epithelial development, tissue homeostasis, and inflammatory responses. It activates pro-forms of proteins like urokinase plasminogen activator (uPA) and protease-activated receptors (PARs), influencing extracellular matrix remodeling and cellular signaling. Dysregulation of ST14/matriptase is linked to pathologies, including cancer, where it exhibits dual roles: promoting tumor invasion via proteolytic cascades or suppressing metastasis depending on context. Overexpression is observed in carcinomas of the breast, prostate, and colon, correlating with poor prognosis. ST14 antibodies are widely used in research to study its expression patterns, activation mechanisms, and therapeutic potential. They enable detection in techniques like Western blotting, immunohistochemistry, and flow cytometry. Recent studies explore matriptase inhibitors for cancer treatment, highlighting ST14 antibodies' role in validating target engagement. Additionally, ST14 variants are implicated in genetic disorders like ichthyosis and metabolic diseases, expanding the antibody's relevance in diagnostics and mechanistic studies. Despite progress, challenges remain in understanding context-dependent functions and optimizing therapeutic strategies.